- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05423665
Speckle Tracking Ekkokardiografi som et verktøy for tidlig diagnose av nedsatt fostervekst tvillingsvangerskap (HEART)
Speckle Tracking Ekkokardiografi som et verktøy for tidlig diagnose av nedsatt fostervekst i tvillingsvangerskap
In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Fetal growth restriction (FGR) is diagnosed in 5-10% of the pregnancies. After preterm birth, it is the second leading cause of perinatal morbidity and mortality. Twin pregnancies have a higher occurrence of FGR than singletons, in monochorionic (MC) twin pregnancies it's diagnosed in 19.7% of the cases and in dichorionic (DC) twin pregnancies in 10.5% of the cases. Fetuses with FGR are at greater risk of perinatal morbidity and mortality and even long-term health defects. From a public health perspective, it's important to correctly diagnose FGR to adjust the antenatal and postnatal care and to have more insight into the factors influencing early onset cardiovascular disease. STE has a strong predictive value for cardiovascular function, therefore it would be a promising tool to add in the routine pregnancy clinical care. Speckle tracking echocardiography (STE) is a relative new technique especially in the pregnancy follow up, which permits offline calculation of myocardial velocities and deformation parameters. These parameters, including strain and strain rate, provide information about the fetal myocardial function. Apart from investigating if STE can be used for the prediction of FGR, we will also investigate the association between fetal exposure to air pollution and in utero cardiac remodeling. Indeed, it is known that inhalation of particulate matter (e.g. black carbon) during the pregnancy can reach the placenta and lead to alterations in the placenta's function including increases in oxidative stress markers. Early life exposure to black carbon has been associated with adverse cardiovascular health outcomes and reduction of fetal growth, especially in multiple gestation pregnancies.
In this project we will include 2 time points during the pregnancy, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 20 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Eline Meireson
- Telefonnummer: 0032 9 332 78 17
- E-post: eline.meireson@uzgent.be
Studiesteder
-
-
-
Ghent, Belgia, 9000
- Rekruttering
- Ghent University Hospital
-
Ta kontakt med:
- Kristien Roelens, prof. dr.
-
Leuven, Belgia, 3000
- Har ikke rekruttert ennå
- Universitair ziekenhuis Leuven
-
Ta kontakt med:
- Liebeth Lewie, prof. dr.
-
-
-
-
-
Eindhoven, Nederland, 5631
- Har ikke rekruttert ennå
- Maxima medical center
-
Ta kontakt med:
- Judith van Laar, dr.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The number of subjects that will be included in this study is: 600 neonates (200 twin pairs and 200 singletons) and 400 pregnant mothers.
The fetuses are divided into following sub-groups:
- Appropriately grown
- Fetal growth restricted
- Selective fetal growth restricted (specific for twins)
Beskrivelse
Inclusion Criteria:
- Singleton or dichorionic twin pregnancy
- Pregnant women 21 weeks ( ± 2 weeks) of gestation at the first visit
- Women ≥ 18 years
Exclusion Criteria:
- Women pregnant of multiples of higher order (≥3 siblings) Monochorionic twin pregnancy
- Fetal arrhythmia
- Known fetal congenital or genetic abnormalities
- Any suspicion of congenital fetal anomalies that might influence fetal cardiac function
- Pre-existing maternal hypertensive disease
- Autoimmune disease including systemic lupus erythematosus
- History of stillbirth
- Diabetes mellitus (mother)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Fetal growth restricted
Observation of cardiac remodeling perinatal and postnatal |
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth |
|
Appropriately grown
Observation of cardiac remodeling perinatal and postnatal |
blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess the change in strain measured by speckle tracking echocardiography as a tool for early diagnosis of impaired fetal growth in multiple gestations
Tidsramme: Prenatal to 1-3 days after birth
|
to determine the change in fetal strain and strain rate in twin pregnancies in comparison with fetal growth |
Prenatal to 1-3 days after birth
|
|
To determine the intra-pair differences in fetal growth and strain (cardiac remodeling) in multiple gestations.
Tidsramme: Prenatal to 1-3 days after birth
|
to compare changes in strain and strain rate with fetal growth within 1 twin pair |
Prenatal to 1-3 days after birth
|
|
To compare the strain values (cardiac remodeling) between singletons and twin pregnancies
Tidsramme: Prenatal to 1-3 days after birth
|
to compare the changes in strain and strain rate between singletons and twin pregnancies |
Prenatal to 1-3 days after birth
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To investigate the association between placenta functioning and in utero cardiac remodeling
Tidsramme: Prenatal to 1-3 days after birth
|
to evaluate placenta insufficiency (Doppler ultrasound, biochemical marker) with strain and strain rate |
Prenatal to 1-3 days after birth
|
|
To explore in utero cardiac remodeling in association with neonatal cardiovascular health
Tidsramme: Prenatal to 1-3 days after birth
|
to evaluate strain and strain rate with the neonatale blood pressure and heart rate |
Prenatal to 1-3 days after birth
|
|
To study the association between prenatal air pollution exposure and in utero cardiac remodeling
Tidsramme: Prenatal to 1-3 days after birth
|
to evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with strain and strain rate |
Prenatal to 1-3 days after birth
|
|
To investigate placenta functioning as a mediator between air pollution and cardiac remodeling
Tidsramme: Prenatal to 1-3 days after birth
|
To evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with placenta insufficiency (biochemical marker, Doppler ultrasound) |
Prenatal to 1-3 days after birth
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Kristien Roelens, University Hospital, Ghent
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Patologiske prosesser
- Patologiske tilstander, anatomiske
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Graviditetskomplikasjoner
- Fostersykdommer
- Vekstforstyrrelser
- Morkake sykdommer
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Fosterveksthemming
- Ventrikulær ombygging
- Placental insuffisiens
- Undersøkelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Prøvehåndtering
Andre studie-ID-numre
- ONZ-2022-0193
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .